Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis

Bibliography

• CHU CQ, FIELD M, FELDMANN M, MAINI RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. (1991) 34:1125-1132.
   PubMed Web of Science ®Google Scholar
• CAMUSSI G, LUPIA E: The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs (1998) 55:613-620.
   PubMed Web of Science ®Google Scholar
• BONIFATI C, AMEGLIO F: Cytokines in psoriasis. Int. J. Dermatol. (1999) 38:241-251.
   PubMed Web of Science ®Google Scholar
• BONIFATI C, CARDUCCI M, CORDIALI FEI P et al.: Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients: relationships with disease severity. Clin. Exp. Dermatol. (1994) 19:383-387.
   PubMed Web of Science ®Google Scholar
• GRATACOS J, COLLADO A, FILELLA X et al.: Serum cytokines (IL-6, TNF-α, IL-1 β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol. (1994) 33:927-931.
   PubMedGoogle Scholar
• FELDMANN M: The cytokine network in rheumatoid arthritis: definition of TNF α as a therapeutic target. J. R. Coll. Physicians Lond. (1996) 30:560-570.
   PubMedGoogle Scholar
• BUTLER DM, MAINI RN, FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. (1995) 6:225-230.
   PubMed Web of Science ®Google Scholar
• DAVIS JC: Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin. Arthritis Rheum. (2004) 34:668-677.
   Web of Science ®Google Scholar
• HARAOUI B: Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin. Arthritis Rheum. (2005) 34(5 Suppl.1):7-11.
   PubMed Web of Science ®Google Scholar
• BECKHAM JC, CALDWELL DS, PETERSON BL et al.: Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J. Clin. Immunol. (1992)12:353-361.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38:499-505.
   PubMed Web of Science ®Google Scholar
• BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum. (2000) 43:1346-1352.
   PubMed Web of Science ®Google Scholar
• CATRINA AI, LAMPA J, ERNESTAM S et al.: Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) (2002) 41:484-489.
   PubMed Web of Science ®Google Scholar
• CATRINA AI, TROLLMO C, AF KLINT E et al.: Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joint. Arthritis Rheum. (2005) 52:61-71.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124:1774-1785.
   PubMed Web of Science ®Google Scholar
• CATRINA AI, AF KLINT E, ERNESTAM S et al.: Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum. (2006) 54:76-81.
   PubMedGoogle Scholar
• BOIRIVANT M, MARINI M, DI FELICE G et al.: Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology (1999) 116:557-565.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, CHAMIAN F, MASUD S et al.: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. (2005) 175:2721-2729.
   PubMed Web of Science ®Google Scholar
• LIZZUL PF, APHALE A, MALAVIYA R et al.: Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J. Invest. Dermatol. (2005) 124:1275-1283.
   PubMed Web of Science ®Google Scholar
• KORTH-BRADLEY JM, RUBIN AS, HANNA RK, SIMCOE DK, LEBSACK ME: The pharmacokinetics of etanercept in healthy volunteers. Ann. Pharmacother. (2000) 34:161-164.
   PubMed Web of Science ®Google Scholar
• KREMER J, SPENCER-GREEN G, HANNA R, KORTH-BRADLEY J: Embrel (etanercept) pharmacokinetics in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. (2000) 43(Suppl): S976.
   Google Scholar
• YIM DS, ZHOU H, BUCKWALTER M, NESTOROV I, PECK CC, LEE H: Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J. Clin. Pharmacol. (2005) 45:246-256.
   PubMed Web of Science ®Google Scholar
• NESTOROV I, ZITNIK R, DEVRIES T, NAKANISHI AM, WANG A, BANFIELD C: Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J. Clin. Pharmacol. (2006) 62:435-445.
   PubMed Web of Science ®Google Scholar
• ZHOU H, BUCKWALTER M, BONI J et al.: Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. (2004) 42:267-276.
   PubMed Web of Science ®Google Scholar
• NESTOROV I: Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum. (2005) 34(5 Suppl. 1):12-18.
   PubMed Web of Science ®Google Scholar
• ZHOU H: Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol. (2005) 45:490-497.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC, SCHIFF MH, KREMER JM et al.: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50:353-363.
   PubMed Web of Science ®Google Scholar
• NESTOROV I, LEBSACK M, DEVRIES T, BURGE T: Pharmacokinetics of etanercept after once weekly subcutaneous administration of 50 mg doses to rheumatoid arthritis patients [abstract]. Ann. Rheum. Dis. (2003) 62(Suppl. 1):182.
   PubMedGoogle Scholar
• VAN DER HEIJDE D, DA SILVA JC, DOUGADOS M et al.: Etanercept Study 314 Investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2006) 65:1572-1577.
   PubMed Web of Science ®Google Scholar
• LEE H, KIMKO HC, ROGGE M, WANG D, NESTOROV I, PECK CC: Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin. Pharmacol. Ther. (2003) 73:348-365.
   PubMed Web of Science ®Google Scholar
• SORAN O, FELDMAN AM, SCHNEIDER VM, HANNA R, MANN DL, KORTH-BRADLEY JM: The pharmacokinetics of etanercept in patients with heart failure. Br. J. Clin. Pharmacol. (2001) 51:191-192.
   PubMed Web of Science ®Google Scholar
• ZHOU H, PARKS V, PATAT A, LE COZ F, SIMCOE D, KORTH-BRADLEY J: Absence of a clinically relevant interaction between etanercept and digoxin.J. Clin. Pharmacol. (2004) 44:1244-1251.
   PubMed Web of Science ®Google Scholar
• ZHOU H, PATAT A, PARKS V, BUCKWALTER M, METZGER D, KORTH-BRADLEY J: Absence of a pharmacokinetic interaction between etanercept and warfarin. J. Clin. Pharmacol. (2004) 44:543-550.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, COHEN S, MORELAND L et al.: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. (2004) 50:1412-1419.
   PubMed Web of Science ®Google Scholar
• ZHOU H, MAYER PR, WAJDULA J, FATENEJAD S: Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J. Clin. Pharmacol. (2004) 44:1235-1243.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, MARGOLIES G, HECK LW, SAWAY A, BLOSCH C, HANNA R, KOOPMAN WJ: Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. (1996) 23:1849-1855.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337: 141-147.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis: a randomized, controlled study. Ann. Intern. Med. (1999) 130: 478-486.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, COHEN SB, FLEISCHMANN RM, BAUMGARTNER SW, SCHIFF MH et al.: Safety and efficacy of up to 5 years of etanercept (Enbrel) therapy in rheumatoid arthritis [abstract]. Ann. Rheum. Dis. (2002) 61(Suppl. 1):FRI0078.
   Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant METHOTREXATE: the ARMADA trial. Arthritis Rheum. (2003) 48:35-45.
   PubMed Web of Science ®Google Scholar
• MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932-1939.
   PubMed Web of Science ®Google Scholar
• KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 363:675-681.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340:253-259.
   PubMed Web of Science ®Google Scholar
• KREMER J,WEINBLATT M, BANKHURST AD et al.: Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. (2003) 48:1493-1499.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE D, KLARESKOG L, WAJDULA J, PEDERSEN R , FATENEJAD S: Sustained halting of joint damage with combination etanercept and methotrexate: 3-year results from the TEMPO trial [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl. 2):509
   Google Scholar
• MARTIN MOLA E, VAN DER HEIJDE D, DE MELO GOMES J et al.: Sustained clinical efficacy and safety of combination therapy with etanercept plus methotrexate in RA patients through 4 years: TEMPO trial extension results [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl. 2):331.
   Google Scholar
• VAN DER HEIJDE D, MARTÍN MOLA E, LUUKKAINEN R et al.: The addition of etanercept to methotrexate and methotrexate to etanercept monotherapies improves clinical efficacy in RA patients despite low moderate disease activity at baseline: results of the TEMPO extension trial (year 4) [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl 2):508
   PubMedGoogle Scholar
• VAN VOLLENHOVEN R, ERNESTAM S, HARJU A, BRATT J, KLARESKOG L: Etanercept versus etanercept plus methotrexate: a registry based study suggesting that the combination is clinically more efficacious. Arthritis Res. Ther. (2003) 5: 347-351.
   PubMed Web of Science ®Google Scholar
• VAN RIEL PL, TAGGART AJ, SANY J et al.: Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to Methotrexate: The ADORE study. Ann. Rheum. Dis. (2006) 65:1478-1483.
   PubMed Web of Science ®Google Scholar
• BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1586-1593.
   PubMed Web of Science ®Google Scholar
• GENOVESE M, BATHON J, MARTIN R et al..: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. (2002) 46:1443-1451.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, BATHON JM, FLEISCHMANN RM et al.: Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J. Rheumatol. (2005) 32:1232-1242.
   PubMed Web of Science ®Google Scholar
• ERRA A, MORENO E, GUANHON L et al.: Experience in the switch from infliximab to etanercept, or vice versa, in rheumatoid arthritis patients [abstract]. Ann. Rheum. Dis. (2002) 61(Suppl. 1):379.
   PubMed Web of Science ®Google Scholar
• BUCH MH: Do patients with rheumatoid arthritis with high disease activity on infliximab demonstrate improvement on etanercept? [abstract]. Ann. Rheum. Dis. (2003) 62(Suppl. 1):181.
   Google Scholar
• HARAOUI B, KEYSTONE EC, THORNE JC et al.: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J. Rheumatol. (2004) 31:2356-2359.
   PubMed Web of Science ®Google Scholar
• VAN VOLLENHOVEN R, HARJU A, BRANNEMARK S, KLARESKOG L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann. Rheum. Dis. (2003) 62:1195-1198.
   PubMed Web of Science ®Google Scholar
• IANNONE F, TROTTA F, MONTECUCCO C et al.: Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab due to side effects. Ann. Rheum. Dis. (2007) 66:249-252.
   PubMed Web of Science ®Google Scholar
• LOVELL DJ, GIANNINI EH, REIFF A, CAWKWELL GD et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. (2000) 342:763-769.
   PubMed Web of Science ®Google Scholar
• LOVELL DJ, GIANNINI EH, REIFF A et al.: Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. (2003) 48:218-226.
   PubMed Web of Science ®Google Scholar
• LOVELL DJ, REIFF A, JONES OY et al.: Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. (2006) 56:1987-1994.
   Google Scholar
• QUARTIER P, TAUPIN P, BOURDEAUT F et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. (2003) 48:1093-101.
   PubMed Web of Science ®Google Scholar
• TWILT1 M, CATE T , VAN ROSSUM MAJ , WULFFRAAT NM: Long term follow-up of etanercept in the treatment of juvenile idiopathic arthritis; the Dutch national study [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl 2):572.
   Google Scholar
• MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385-390.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, KIVITZ RJ, BURCH FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. (2004) 50:2264-2272.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, KIVITZ RJ, BURCH FX et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J. Rheumatol. (2006) 33:712-721.
   PubMed Web of Science ®Google Scholar
• GORMAN JD, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N. Engl. J. Med. (2002) 346:1349-1356.
   PubMed Web of Science ®Google Scholar
• BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. (2003) 48:1667-1675.
   PubMed Web of Science ®Google Scholar
• BARALIAKOS J, BRANDT J , LISTING J et al.: Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. (2005) 53:856-863.
   PubMed Web of Science ®Google Scholar
• DAVIS JC JR, VAN DER HEIJDE D et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. (2003) 48: 3230-3236.
   PubMed Web of Science ®Google Scholar
• BARALIAKOS X, DAVIS J, TSUJI W, BRAUN J: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum. (2005) 52:1216-1223.
   PubMed Web of Science ®Google Scholar
• DAVIS JC, VAN DER HEIJDE DM, BRAUN J et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann. Rheum. Dis. (2005) 64:1557–1562.
   PubMed Web of Science ®Google Scholar
• CALIN A, DIJKMANS BA, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63:1594-600.
   PubMed Web of Science ®Google Scholar
• SIEPER J, DIJKMANS B.A.C, VAN DER LINDEN S et al.. Long term efficacy and safety of etanercept in patients with ankylosing spondylitis: 148 to 160 week analysis from an ongoing trial [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl. 2): 437.
   Google Scholar
• VAN DER HEIJDE D, KLARESKOG L, BAKER P, WAJDULA J, FATENEJAD S: Etanercept combined with methotrexate is well tolerated for 3 years: results from the trial of etanercept and methotrexate with radiographic and patient outcomes (TEMPO) [abstract].. Ann. Rheum. Dis. (2006) 65(Suppl. 2):510.
   Google Scholar
• FLEISCHMANN R, BAUMGARTNER SW, WEISMAN MH, LIU T, WHITE B, PELOSO P: Long term safety of etanercept in elderly subjects with rheumatic diseases.Ann. Rheum. Dis. (2006) 65:379-384.
   PubMed Web of Science ®Google Scholar
• ELLERIN T, RUBIN RH, WEINBLATT ME: Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. (2003) 48:3013-3022.
   PubMed Web of Science ®Google Scholar
• KHANNA D, MCMAHON M, FURST DE: Safety of tumour necrosis factor-α antagonists. Drug Saf. (2004) 27:307-324.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC: Safety of biologic therapies--an update. J. Rheumatol. Suppl. (2005) 74:8-12.
   Google Scholar
• MOHAN VP, SCANGA CA, YU K et al.: Effects of tumor necrosis factor α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. (2001) 69:1847- 55.
   PubMed Web of Science ®Google Scholar
• WALLIS RS, BRODER MS, WONG JY, HANSON ME, BEENHOUWER DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. (2004) 38:1261-1265.
   PubMed Web of Science ®Google Scholar
• WALLIS RS, BRODER M, WONG JY, BEENHOUWER DO: Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. (2004) 39:1254-1255.
   PubMed Web of Science ®Google Scholar
• GOMEZ-REINO JJ, CARMONA L, VALVERDE VR MOLA EM, MONTERO MD; BIOBADASER GROUP: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. (2003) 48:2122-2127.
   PubMed Web of Science ®Google Scholar
• ASKLING J, FORED CM, BRANDT L et al.: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. (2005) 52:1986-1992.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K, ANDERSON J, URBANSKY K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. (2004) 50:372-379.
   PubMed Web of Science ®Google Scholar
• FURST DE, WALLIS R, BRODER M, BEENHOUWER DO:Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. (2006) 36:159-167.
   PubMed Web of Science ®Google Scholar
• MARIETTE X, SALMON D AND GROUP RATIO: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann. Rheum. Dis. (2004) 62:791.
   Google Scholar
• FURST DE, CUSH J, KAUFMANN S SIEGEL J, KURTH R: Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biologic agents. Ann. Rheum. Dis. (2002) 61:62-63.
   PubMed Web of Science ®Google Scholar
• CARMONA L, GOMEZ-REINO JJ, RODRIGUEZ-VALVERDE V t al.; BIOBADASER GROUP: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. (2005) 52:1766-1772.
   PubMed Web of Science ®Google Scholar
• DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP; BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. (2006) 54:2368-2376.
   PubMed Web of Science ®Google Scholar
• LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. (2005) 52:3403-3412.
   PubMed Web of Science ®Google Scholar
• DESAI SB, FURST DE: Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol. (2006) 20:757-790.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC: Safety of biologic therapies:an update. J. Rheumatol. (2005) 32(Suppl. 74):8-12.
   Web of Science ®Google Scholar
• BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM:Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46:3151-3158.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50:1740-1751.
   PubMed Web of Science ®Google Scholar
• ASKLING J, FORED CM, BRANDT L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann. Rheum. Dis. (2005) 64:1421- 6.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: The risk of lymphoma among persons with rheumatoid arthritis in the United States: no association with anti-TNF therapy [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl. 2):512-513.
   Google Scholar
• GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patient with rheumatoid arthritis, but may be associated with an increased risk of lymphoma. Ann. Rheum. Dis. (2005) 64:699-703.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: The association of new cases of cancer with biologic therapy [abstract]. Arthritis Rheum. (2006) 54(Suppl.):S549.
   Google Scholar
• OKADA SK, SIEGEL JN: Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA (2006) 296:2201-2202.
   PubMed Web of Science ®Google Scholar
• BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 295:2275-2285.
   PubMed Web of Science ®Google Scholar
• STONE JH, HOLBROOK JT, MARRIOTT MA et al.: Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. (2006) 54:1608-1618.
   PubMed Web of Science ®Google Scholar
• KHANNA D, MCMAHON M, FURST DE: Anti-tumor necrosis factor α therapy and heart failure: what have we learned and where do we go from here?. Arthritis Rheum. (2004) 50:1040-1050.
   PubMed Web of Science ®Google Scholar
• DESWAL A, BOZKURT B, SETA Y, PARILTI-EISWIRTH S et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel,etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224-3226.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL)in patients with advanced heart failure. Circulation (2001) 103:1044-1047.
   PubMed Web of Science ®Google Scholar
• COLETTA AP, CLARK AL, BANARJEE P, CLELAND JG: Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur. J. Heart Fail. (2002) 4:559-561.
   PubMed Web of Science ®Google Scholar
• MANN DL, MCMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594-602.
   PubMed Web of Science ®Google Scholar
• KWON HJ, COTE TR, CUFFE MS, KRAMER JM, BRAUN MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138:807-811.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. (2004) 116:305-311.
   PubMed Web of Science ®Google Scholar
• NELSON DR, LIM HL, MAROUSIS CG et al.: Activation of tumor necrosis factor-a system in chronic hepatitis C virus infection. Dig Dis. Sci. (1997) 42:2487- 94.
   PubMed Web of Science ®Google Scholar
• PARKE FA, REVEILLE JD: Anti-tumour necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. (2004) 51:800-804.
   PubMed Web of Science ®Google Scholar
• MAGLIOCCO MA, GOTTLIEB AB: Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J. Am. Acad. Dermatol. (2004) 51:580-584.
   PubMed Web of Science ®Google Scholar
• KHANNA M, SHIRODKAR MA, GOTTLIEB AB: Etanercept therapy in patients with autoimmunity and hepatitis. J. Dermatolog. Treat. (2003) 14:229-232.
   Google Scholar
• PETERSON JR, HSU FC, SIMKIN PA,WENER MH: Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann. Rheum. Dis. (2003) 62:1078-1082.
   PubMed Web of Science ®Google Scholar
• ROKHSAR C, RABHAN N, COHEN SR: Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J. Am. Acad. Dermatol. (2006) 54:361-362.
   PubMed Web of Science ®Google Scholar
• DE SIMONE C, PARADISI A, CAPIZZI R, CARBONE A, SICILIANO M, AMERIO PL: Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J. Am. Acad. Dermatol. (2006) 54:1102-1104.
   PubMed Web of Science ®Google Scholar
• ROUX CH, BROCQ O, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.Rheumatology (Oxford) (2006) 45:1294-1297.
   PubMed Web of Science ®Google Scholar
• MAROTTE H, FONTANGES E, BAILLY F, ZOULIM F, TREPO C, MIOSSEC P: Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) (2006) 46(1):97-99.
   Google Scholar
• ZEIN NN AND ETANERCEPT STUDY GROUP: Etanercept as an adjuvant to interferon and ribavirin in treatment naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebocontrolled study. J. Hepatol. (2005) 42:315-322.
   PubMed Web of Science ®Google Scholar
• NIEWOLD TB, GIBOFSKY A: Concomitant interferon-α therapy and tumor necrosis factor α inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum. (2006) 54:2335-2337.
   PubMed Web of Science ®Google Scholar
• TORRE D, ZEROLI C, GIOLA M et al.: Serum levels of interleukin-1 α, interleukin-1β, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin. Infect. Dis. (1994) 18:194-198.
   PubMed Web of Science ®Google Scholar
• FANG JW, SHEN WW, MEAGER A, LAU JY: Activation of the tumor necrosis factor-α system in the liver in chronic hepatitis B virus infection. Am. J. Gastroenterol. (1996) 91:748-753.
   PubMed Web of Science ®Google Scholar
• CALABRESE LH, ZEIN N, VASSILOPOULOS D: Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. (2004) 63(Suppl. 2):18-24.
   Google Scholar
• SELMAJ KW: Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann. Rheum. Dis. (2000) 59(Suppl. 1):94-102.
   PubMedGoogle Scholar
• LOCK C, OKSENBERG J, STEINMAN L: The role of TNFα and lymphotoxin in demyelinating disease. Ann. Rheum. Dis. (1999) 58(Suppl. I):121–128.
   Web of Science ®Google Scholar
• MARTINEZ-TABOADA VM, VAL-BERNAL JF et al.: Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand. J. Rheumatol. (2006) 35:322-323.
   PubMed Web of Science ®Google Scholar
• AL SAIEG N, LUZAR MJ: Etanercept induced multiple sclerosis and transverse myelitis. J. Rheumatol. (2006) 33:1202-1204.
   PubMed Web of Science ®Google Scholar
• TITELBAUM DS, DEGENHARDT A, KINKEL RP: Anti-tumor necrosis factor α-associated multiple sclerosis. Am. J. Neuroradiol. (2005) 26:1548-1550.
   PubMed Web of Science ®Google Scholar
• KUNZMANN S, WARMUTH-METZ M, GIRSCHICK HJ: Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease. Scand. J. Rheumatol. (2005) 34:76-78.
   PubMed Web of Science ®Google Scholar
• NOGUERA-PONS R, BORRAS-BLASCO J, ROMERO-CRESPO I, ANTON-TORRES R, NAVARRO-RUIZ A, GONZALEZ-FERRANDEZ JA: Optic neuritis with concurrent etanarcept and isoniazid therapy. Ann. Pharmacother. (2005) 39:2131-2135.
   PubMed Web of Science ®Google Scholar
• RICHEZ C, BLANCO P, LAGUENY A, SCHAEVERBEKE T, DEHAIS J: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers. Neurology (2005) 64:1468-1470.
   PubMed Web of Science ®Google Scholar
• VAN DER LAKEN CJ, LEMS WF, VAN SOESBERGEN RM, VAN DER SANDE JJ, DIJKMANS BA: Paraplegia in a patient receiving anti-tumor necrosisfactor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum. (2003) 48: 269-270.
   PubMedGoogle Scholar
• SICOTTE NL, VOSKUHL RR: Onset of multiple sclerosis associated with anti-TNF therapy. Neurology (2001) 57:1885-1888.
   PubMed Web of Science ®Google Scholar
• MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862-2869.
   PubMed Web of Science ®Google Scholar
• HORNEFF G, SCHMELING H, BIEDERMANN T et al.: Paediatric Rheumatology Collaborative Group: the German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. (2004) 63:1638-1644.
   PubMed Web of Science ®Google Scholar
• FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann. Rheum. Dis. (2006) 65(Suppl. 3):2-15.
   PubMed Web of Science ®Google Scholar
• ETANERCEPT: (Enbrel) package insert (2003).
   Google Scholar
• KLARESKOG L, WAJDULA J, YEH P, FATENEJAD S, ETANERCEPT STUDY 301 INVESTIGATORS: Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes after five years of treatment with etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. (2005) 52(Suppl. 1): 348.
   Google Scholar
• CARAMASCHI P, BIASI D, COLOMBATTI M et al.: Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol. Int. (2006) 26:209-214.
   PubMed Web of Science ®Google Scholar
• DE RYCKE L, BAETEN D, KRUITHOF E, VAN DEN BOSCH F, VEYS EM, DE KEYSER F: Infliximab, but not etanercept, induces IgM anti-doublestranded DNA autoantibodies as main antinuclear reactivity. Arthritis Rheum. (2005) 52:2192-201.
   PubMed Web of Science ®Google Scholar
• SHAKOOR N, MICHALSKA M, HARRIS CA, BLOCK JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579-580.
   PubMed Web of Science ®Google Scholar
• MOHAN AK, EDWARDS ET, COTE TR, SIEGEL JN, BRAUN MM: Drug-induced systemic lupus erythematosus and TNF-α blockers. Lancet (2002) 360:646.
   Google Scholar
• RICHEZ C, BLANCO P, DUMOULIN C, SCHAEVERBEKE T: Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease. Clin. Exp. Rheumatol. (2005) 23:273.
   PubMedGoogle Scholar
• LEPORE L, MARCHETTI F, FACCHINIS, LEONE V, VENTURA A: Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. (2003) 21:276-277.
   PubMed Web of Science ®Google Scholar
• CARLSON E, ROTHFIELD N: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. (2003) 48:1165-1166; author reply 1166.
   PubMed Web of Science ®Google Scholar
• CAIRNS AP, DUNCAN MK, HINDER AE, TAGGART AJ: New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:1031-1032.
   PubMed Web of Science ®Google Scholar
• DE BANDT M, SIBILIA J, LE LOET X et al.: Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy: a French national survey. Arthritis Res. Ther. (2005) 7:545-551.
   PubMed Web of Science ®Google Scholar
• JONSDOTTIR T, FORSLID J, VAN VOLLENHOVEN A et al.: Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann. Rheum. Dis. (2004) 63:1075-107 8.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141-147.
   PubMed Web of Science ®Google Scholar
• ROUX CH, BROCQ O, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-{α} therapy. Rheumatology (Oxford) (2006) 46(4):695-698.
   PubMed Web of Science ®Google Scholar
• CARTER JD, VALERIANO J, VASEY FB: Tumor necrosis factor-α inhibition and VATER association: a causal relationship. J. Rheumatol. (2006) 33:1014-1017.
   PubMed Web of Science ®Google Scholar
• SILLS ES, PERLOE M, TUCKER MJ, KAPLAN CR, PALERMO GD: Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am. J. Reprod. Immunol. (2001) 46:366-368.
   PubMed Web of Science ®Google Scholar
• WALLACE DJ, WEISMAN MH: The use of etanercept and other tumor necrosis factor-α blockers in infertility:it's time to get serious. J. Rheumatol.. (2003) 30:1897-1899.
   PubMed Web of Science ®Google Scholar
• RUMP JA, USADE S, SCHONBORN H: Pregnancy and etanercept - two cases and follow up [abstract]. Proc. Eur. League Against Rheum. (2004) 63(Suppl. 1): THU0248.
   Google Scholar
• FEYERTAG J, DINHOF G, SALZER H, DUNKY A: Pregnancy in a rheumatoid arthritis patient treated with Etanercept. Proc. Eur. League Against Rheum. (2004) 63(Suppl. 1):THU0297.
   Google Scholar
• CHAKRAVARTY EF, SANCHEZ-YAMAMOTO D, BUSH TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J. Rheumatol. (2003) 30:241- 6.
   PubMed Web of Science ®Google Scholar
• HYRICH KL, SYMMONS DP, WATSON KD, SILMAN AJ; BRITISH SOCIETY, FOR RHEUMATOLOGY BIOLOGICS REGISTER: Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. (2006) 54:2701-2702.
   PubMed Web of Science ®Google Scholar
• ELLISH NJ, SABODA K, O’CONNOR J, NASCA PC, STANEK EJ, BOYLE C: A prospective study of early pregnancy loss. Arthritis Rheum. (1996) 11:406–12.
   Google Scholar
• ZINAMAN MJ, CLEGG ED, BROWN CC, O’CONNOR J, SELEVAN SG: Estimates of human fertility and pregnancy loss. Fertil. Steril. (1996) 65:503–509.
   PubMed Web of Science ®Google Scholar
• CHAMBERS CD, JOHNSON DL, JONES KL, THE OTIS COLLABORATIVE RESEARCH GROUP: Pregnancy outcome in women exposed to anti-TNF-α medications: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Arthritis Rheum. (2004) 50(Suppl.): S479–S480.
   Google Scholar
• CHAKRAVARTY EF, NELSON L, KRISHNAN E: Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. (2006) 54:899-907.
   PubMed Web of Science ®Google Scholar
• SKOMSVOLL JF, OSTENSEN M, IRGENS LM, BASTE V: Obstetrical and neonatal outcome in pregnant patients with rheumatic disease.Scand. J. Rheumatol. Suppl. (1998) 107:109–112.
   Google Scholar
• BOWDEN AP, BARRETT JH, FALLOW W, SILMAN AJ: Women with inflammatory polyarthritis have babies of lower birth weight. J. Rheumatol. (2001) 28:355-359.
   PubMed Web of Science ®Google Scholar
• NELSON JL, OSTENSEN M: Pregnancy and rheumatoid arthritis. Rheum. Dis. Clin. North Am. (1997) 23:195–212.
   Google Scholar